Pharma News: Lilly, Amylin & Alkermes Get European Nod; Pfizer Announced Arthritis Study Results

682 views
  • About
  • Add to
Eli Lilly (LLY), Amylin Pharmaceuticals (AMLN) and Alkermes (ALKS) said today the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of type 2 diabetes treatment Bydureon in the European Union. The application to the European regulatory authorities is for use of the drug as a once-weekly 2 mg dose to improve glycemic control in adults.

0 comments